Expressions of IGF-1R and IGFBP-3 in colon cancer metastasis and their correlations with lymphatic metastasis

doi:10.3760/cma.j.issn.1673422X.2015.02.005

Abstract

Abstract: ObjectiveTo investigate the expressions of insulinlike growth factor receptor1 (IGF1R) and insulinlike growth factor binding protein3 (IGFBP3) and their correlations with clinicopathological parameters in the primary colon cancer, as well as their roles in lymph node metastasis of colon cancer. MethodsThe expressions of IGF1R and IGFBP3 in 78 cases of colon cancer tissues and 78 cases of normal colon mucosa tissues were detected by SP immunohistochemical technology and the correlations between the expressions and the clinical pathological parameters of colon cancer were analyzed. ResultsThe positive rate of IGF1R in colon cancer (66.7%, 52/78) was significantly higher than that in control group (24.4%, 19/78), χ2=28.150, P=0.000. The positive rate of IGFBP3 in colon cancer (73.1%, 57/78) was significantly lower than that in control group (89.7%, 70/78), χ2=7.158, P=0.007. IGF1R expression in colon cancer was significantly correlated with the invasion (χ2= 5.804, P=0.016), TNM stage (χ2=5.246, P=0.022) and lymph node metastasis (χ2=12.955, P=0.000). IGFBP3 expression in colon cancer was significantly correlated with the TNM stage (χ2=7.096, P=0.008), lymph node metastasis (χ2=5.893, P=0.015) and distant metastasis (P=0.003). Both with other factors had no significant correlation (P>0.05). IGF1R expression and IGFBP3 expression showed a negative correlation (r=-0.245, P=0.03). ConclusionThe over expression of IGF1R and low expression of IGFBP3 are associated with TNM stage and lymph node metastasis in colon cancer. IGF1R and IGFBP3 may become new targets of the treatment of colon cancer.

Key words: Colon cancer, Receptor, IGF type 1, Insulinlike growth factor binding protein 3, Immunohistochemistry

Li Tingting, Kang Junpeng, Guo Shuqin. Expressions of IGF-1R and IGFBP-3 in colon cancer metastasis and their correlations with lymphatic metastasis[J]. Journal of International Oncology, 2015, 42(2): 95-98.

References

［1］ Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of Cancer in 2008: GLOB0CAN 2008［J］. Int J Cancer, 2010, 127 (12): 2893-2917. ［2］ Baserga R. Customizing the targeting of IGF1 receptor［J］. Future Oncol, 2009, 5(1): 43-50. ［3］崔艳欣, 刘玲, 杨阅楼, 等. 结直肠腺瘤患者IGF1、IGF1R的表达及其与血清IGFl水平的关系［J］. 胃肠病学, 2013, 18(2): 114-117. ［4］ Annenkov A. The insulinlike growth factor (IGF) receptor type 1 (IGF1R) as an essential component of the signaling network regulating neurogenesis［J］. Mol Neurobiol, 2009, 40(3): 195-215. ［5］ Gallagher EJ, Leroith D. Minireview: IGF, insulin, and cancer［J］. Endocrinology, 2011, 152(7): 2546-2551. ［6］ Georges RB, Adwan H, Hamdi H, et al. The insulinlike growth factor binding proteins 3 and 7 are associated with colorectal cancer and liver metastasis［J］. Cancer Biol Ther, 2011, 12(1): 69-79. ［7］ Sichani MM, Yazdi FS, Moghaddam NA, et al. Prognostic value of insulinlike growth factorⅠ receptor expression in renal cell carcinoma［J］. Saudi J Kidney Dis Traspl, 2010, 21(1): 69-74. ［8］ Wang T, Ge G, Ding Y, et al. MiR503 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R and BCL2［J］. Chin Med J (Engl), 2014, 127(12): 23572362. ［9］ Yavari K, Taghikhani M, Ghannadi Maraqheh M, et al. Downregulation of IGFⅠR expression by RNAi inhibits proliferation and enhances chemosensitization of human colon cancer cells［J］. Int J Colorectal Dis, 2010, 25(1): 916. ［10］武广彬，黄昌明. 胰岛素样生长因子I型受体肿瘤靶向治疗［J］. 国际肿瘤学杂志, 2006, 33(4): 253-256. ［11］ Jiang B, Liu DB, Zhang X, et al. Association of insulin, insulinlike growth factor and insulinlike growth factor binding proteins with the risk of colorectal cancer［J］. Zhonghua Wei Chang Wai Ke Za Zhi, 2009, 12(3): 264-268. ［12］ Chen W, Wang S, Tian T, et al. Phenotypes and genotypes of insulinlike growth factor 1, IGFbinding protein3 and cancer risk: evidence from 96 studies［J］. Eur J Hum Genet, 2009, 17(12): 1668-1675.

[1]	Liao Lihua, Wang Shaohong, Chen Hongcai, Zhao Yongqiang. Value of cell paraffin block immunohistochemistry and pleural effusion CRKL and MIC-1 in the diagnosis of malignant pleural effusion [J]. Journal of International Oncology, 2023, 50(2): 71-75.
[2]	Xue Dong, Xia Xiuliang, Song Dekun, Xiang Tinghai, Wang Jianqiang, Gong Bengang. Expression and clinical significance of cullin 4A in cholangiocarcinoma [J]. Journal of International Oncology, 2019, 46(3): 153-156.
[3]	Duan Fei, Zhang Jinyu, Liu Jing, Ma Zhenfeng, Cui Naipeng, Liu Xianyi, Chen Baoping. Expression and clinical significance of OTUB1 in breast cancer [J]. Journal of International Oncology, 2017, 44(8): 565-568.
[4]	Huang Lijuan, Zhou Bingjuan, Cao Jianjiang, Zhang Nan, Chen Hong, Ma Qiushuang, Zhang Jinku. Expressions and clinical significances of ATF3 and Runx2 in breast carcinoma [J]. Journal of International Oncology, 2017, 44(6): 411-.
[5]	Lin Chenshi, Yang Jiyuan. Expression of RRM1 in gastric adenocarcinoma and its relationship with clinical pathological characteristics [J]. Journal of International Oncology, 2016, 43(5): 343-345.
[6]	Huang Liyong, Pan Jie, Shen Xuning, Jiang Honggang. Expression and significance of Sirtuin 1 in human colorectal cancer [J]. Journal of International Oncology, 2016, 43(3): 188-192.
[7]	ZHANG Zhi-Jin, FU Jun, ZHANG Yu-Hao, GE Cui-Cui, QIN Xian-Ju. Pre-B-cell colony enhancing factor expression and its clinical significance in colorectal cancer [J]. Journal of International Oncology, 2016, 43(12): 896-899.
[8]	Nie Jia, Wu Ning, Zhang Lixia, Huang Yifan, Liu Jun. Expressions of IMP3 in cervical squamous cell carcinoma before and after the therapy of radiation and chemotherapy [J]. Journal of International Oncology, 2016, 43(10): 744-747.
[9]	Chen Xiaoping, Pu Yong, Feng Jingjie, Hua Dong. Expression and clinical significance of S100A11 in non-small cell lung cancer [J]. Journal of International Oncology, 2016, 43(1): 5-7.
[10]	Guo Hongyan, He Lizhen, Zhang Yunfei, Zhang Hong, Jin Huiqin, An Wenwen. Metastasis-associated in colon cancer 1 and its role in cancer [J]. Journal of International Oncology, 2016, 43(1): 32-35.
[11]	WANG Rui-Cai, ZHU Jian-You, ZHANG Hai-Peng, XU Shao-Yan, WANG Ai-Yun. Expressions and clinical signifcances of matrix metalloproteinase13 and p73 in gastric adenocarcinoma [J]. Journal of International Oncology, 2015, 42(8): 576-579.
[12]	Jiang Zhongxiu, Liu Yang, Li Ning, Qi Xiaoying, Zhang Xiaoye. Expression and clinical significance of SIRT-1 and NF-κB in non-small cell lung cancer [J]. Journal of International Oncology, 2015, 42(7): 504-507.
[13]	Hu Siqin, Zhang Minghui, Shi Qiong, Wang Yan. Expression and significance of TTF1 and CgA in small cell lung carcinoma [J]. Journal of International Oncology, 2015, 42(7): 501-503.
[14]	FAN Li-Juan, ZHANG Jian, LIN Fan-Zhong, LI Hong-Yun. Expression and clinically pathological analysis of the protein CDC6 and HOXA5 in esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2015, 42(5): 327-330.
[15]	CHEN Wen-Jun, DONG Chong-Hai, TIAN Zi-Bin. Expression and significance of c-myc and CD24 in colorectal cancer [J]. Journal of International Oncology, 2015, 42(4): 255-258.